If you've got $10,000 to put to work on the ASX, deciding where to invest can feel overwhelming.
To narrow things down, let's take a look at three ASX 200 stocks that analysts think could be quality picks for Aussie investors right now.
Here's why they could form the foundation of a successful $10,000 portfolio today.
Image source: Getty Images
CSL Ltd (ASX: CSL)
CSL is one of Australia's premier healthcare giants, with operations spanning plasma therapies, vaccines, and kidney treatments. Its global reach and significant annual investment in cutting-edge research make it a standout on the ASX 200.
So, with its shares down meaningfully from their highs and trading on much lower than normal multiples, now could be a good time to buy. Especially given how analysts see margin recovery and above-market earnings growth ahead.
Macquarie is very bullish on the company and has an outperform rating and $360.30 price target on its shares.
Life360 Inc. (ASX: 360)
Another ASX 200 stock that could be a buy with the $10,000 is Life360.
Best known for its family safety app, the tech company has consistently delivered impressive results over the past few years. This has continued this year with first quarter FY 2025 revenue up 32% year over year to US$103.6 million and strong subscriber growth.
Its growing user base — now over 83 million monthly active users — and improving profitability signal a company maturing into a sustainable growth story. With further product monetisation opportunities and global expansion plans, Life360 remains a stock with plenty of runway.
Morgan Stanley is a fan of the company and has an overweight rating and $40.00 price target on its shares.
ResMed Inc. (ASX: RMD)
Finally, ResMed could be an ASX 200 stock to buy with the $10,000. It is a global leader in sleep apnoea and respiratory care devices.
Concerns about weight-loss drugs denting demand for its products have faded, with recent earnings showing solid double-digit growth and expanding margins. And the good news is that analysts at Ord Minnett expect this trend to continue.
As a result, with ResMed shares trading at a notable discount to its 10-year average multiple of ~32x earnings, now could be an opportune time to snap them up. Especially investors seeking defensive growth in a proven global leader.
The team at Ord Minnett recently put a buy rating and $46.50 price target on its shares.
